<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="liv16137" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Liver Int</journal-id><journal-id journal-id-type="iso-abbrev">Liver Int</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">LIV</journal-id><journal-title-group><journal-title>Liver International</journal-title></journal-title-group><issn pub-type="ppub">1478-3223</issn><issn pub-type="epub">1478-3231</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11897844</article-id><article-id pub-id-type="pmcid-ver">PMC11897844.1</article-id><article-id pub-id-type="pmcaid">11897844</article-id><article-id pub-id-type="pmcaiid">11897844</article-id><article-id pub-id-type="pmid">39467033</article-id><article-id pub-id-type="doi">10.1111/liv.16137</article-id><article-id pub-id-type="publisher-id">LIV16137</article-id><article-id pub-id-type="other">LIVint-24-01404.R2</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>G&#8208;<styled-content style="fixed-case" toggle="no">CSF</styled-content>&#8212;In Patients With Severe Alcohol&#8208;Associated Hepatitis: A Real&#8208;World Experience</article-title></title-group><contrib-group><contrib id="liv16137-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Singh</surname><given-names initials="RR">Ritu Raj</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8889-869X</contrib-id><xref rid="liv16137-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv16137-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>drhrituraj83@gmail.com</email><email>rsingh56@jhmi.edu</email></address></contrib><contrib id="liv16137-cr-0002" contrib-type="author"><name name-style="western"><surname>Chhabra</surname><given-names initials="P">Puneet</given-names></name><xref rid="liv16137-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="liv16137-cr-0003" contrib-type="author"><name name-style="western"><surname>Dhillon</surname><given-names initials="S">Sonu</given-names></name><xref rid="liv16137-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="liv16137-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>University of Illinois College of Medicine</institution>
<city>Peoria</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><aff id="liv16137-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Johns Hopkins Bloomberg School of Public Health</institution>
<city>Baltimore</city>
<named-content content-type="country-part">Maryland</named-content>
<country country="US">USA</country>
</aff><aff id="liv16137-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Calderdale and Huddersfield NHS Foundation Trust</institution>
<city>Huddersfield</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Ritu Raj Singh (<email>drhrituraj83@gmail.com</email>; <email>rsingh56@jhmi.edu</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>45</volume><issue seq="640">4</issue><issue-id pub-id-type="pmc-issue-id">484013</issue-id><issue-id pub-id-type="doi">10.1111/liv.v45.4</issue-id><elocation-id>e16137</elocation-id><history><date date-type="rev-recd"><day>02</day><month>10</month><year>2024</year></date><date date-type="received"><day>04</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>05</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-13 00:25:36.683"><day>13</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Liver International</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="LIV-45-0.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:LIV-45-0.pdf"/><abstract><title>ABSTRACT</title><sec id="liv16137-sec-0001"><title>Background and Aims</title><p>Severe alcohol&#8208;associated hepatitis (SAH) is associated with high short&#8208;term mortality, and failure of response to corticosteroids is associated with a mortality of ~70%&#8211;80% within 6&#8201;months. Granulocyte colony&#8208;stimulating factor (G&#8208;CSF) has been studied in steroid non&#8208;responders; however, the data are limited.</p></sec><sec id="liv16137-sec-0002"><title>Methods</title><p>This is a multicentre retrospective cohort study. The study period was from January 2016 to November 2023. SAH was defined as alcohol&#8208;associated hepatitis (ICD&#8208;10&#8208;CM codes) with serum bilirubin &#8805;&#8201;5.0&#8201;mg/dL and INR &#8805;&#8201;1.5. Other aetiologies of acute hepatitis and biliary obstruction were excluded. The primary outcome was 90&#8208;day median overall survival in SAH patients treated with G&#8208;CSF compared with standard medical therapy (SMT) or corticosteroids. Propensity score (1:1) matching was performed to control confounding variables.</p></sec><sec id="liv16137-sec-0003"><title>Results</title><p>Among 20&#8201;132 patients with SAH, 10800 (53.65%) were treated with corticosteroids and 224 (1.11%) G&#8208;CSF. The G&#8208;CSF group was younger (45.5 vs. 48.4) White (79.91% vs. 72.40%); however, there was no age or gender difference between G&#8208;CSF and corticosteroid groups. Whites and patients with more comorbidities received G&#8208;CSF more frequently than SMT or corticosteroids. After propensity score matching, 90&#8208;day overall survival was better in patients who received G&#8208;CSF (88.31% vs. 62.36%, <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.01) compared with SMT or corticosteroids (88.31% vs. 74.39%, <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.01). Patients on G&#8208;CSF had better 6&#8208;month transplant&#8208;free survival compared with SMT (83.53% vs. 55.36%, <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001) or corticosteroids (82.89% vs. 60.21%, <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001). Gastrointestinal bleeding was less common in G&#8208;CSF group compared with corticosteroids (5.02% vs. 10.50%, <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001).</p></sec><sec id="liv16137-sec-0004"><title>Conclusions</title><p>A small minority of patients with severe alcohol&#8208;associated hepatitis receive G&#8208;CSF. G&#8208;CSF improves 90&#8208;day overall survival in patients with severe alcohol&#8208;associated hepatitis and is non&#8208;inferior to corticosteroids.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="liv16137-kwd-0001">corticosteroid</kwd><kwd id="liv16137-kwd-0002">G&#8208;CSF</kwd><kwd id="liv16137-kwd-0003">severe alcoholic hepatitis</kwd><kwd id="liv16137-kwd-0004">TriNetX</kwd></kwd-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="9"/><word-count count="5500"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:12.03.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="liv16137-ntgp-0001"><fn fn-type="funding" id="liv16137-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="liv16137-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="liv16137-blkfxd-0001" orientation="portrait"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="liv16137-list-0001"><list-item id="liv16137-li-0001"><p>Severe alcohol&#8208;associated hepatitis is associated with high short&#8208;term mortality without transplant and corticosteroids are the only recommended treatment.</p></list-item><list-item id="liv16137-li-0002"><p>Corticosteroids remain the mainstay of treatment for alcohol&#8208;associated hepatitis and use of G&#8208;CSF is limited.</p></list-item><list-item id="liv16137-li-0003"><p>Our study indicates potential role of G&#8208;CSF in patients with severe alcohol&#8208;associated hepatitis with likely improvement in 90&#8208;day overall survival and 6&#8208;month transplant&#8208;free survival compared with standard medical therapy.</p></list-item></list>
</p></boxed-text>
</p><sec><def-list list-content="abbreviations" id="liv16137-dl-0001"><title>Abbreviations</title><def-item><term id="liv16137-li-0004">G&#8208;CSF</term><def id="liv16137-li-0005"><p>granulocyte colony&#8208;stimulating factor</p></def></def-item><def-item><term id="liv16137-li-0006">HR</term><def id="liv16137-li-0007"><p>hazard ratio</p></def></def-item><def-item><term id="liv16137-li-0008">ICD&#8208;10&#8208;CM</term><def id="liv16137-li-0009"><p>international classification of diseases, 10th revision, clinical modification</p></def></def-item><def-item><term id="liv16137-li-0010">INR</term><def id="liv16137-li-0011"><p>international normalised ratio</p></def></def-item><def-item><term id="liv16137-li-0012">MELD</term><def id="liv16137-li-0013"><p>model for end&#8208;stage liver disease</p></def></def-item><def-item><term id="liv16137-li-0014">RR</term><def id="liv16137-li-0015"><p>risk ratio</p></def></def-item><def-item><term id="liv16137-li-0016">SAH</term><def id="liv16137-li-0017"><p>severe alcohol&#8208;associated hepatitis</p></def></def-item><def-item><term id="liv16137-li-0018">SMT</term><def id="liv16137-li-0019"><p>standard medical therapy</p></def></def-item></def-list></sec><sec sec-type="background" id="liv16137-sec-0007"><label>1</label><title>Background</title><p>Severe alcohol&#8208;associated hepatitis (SAH) portends a poor prognosis and carries a high short&#8208;term mortality. In the absence of treatment, 30%&#8211;50% of patients with SAH succumb to their illness within the first month of presentation [<xref rid="liv16137-bib-0001" ref-type="bibr">1</xref>, <xref rid="liv16137-bib-0002" ref-type="bibr">2</xref>, <xref rid="liv16137-bib-0003" ref-type="bibr">3</xref>]. Corticosteroids are the mainstay of treatment and multiple clinical trials have demonstrated their survival advantage over placebo [<xref rid="liv16137-bib-0002" ref-type="bibr">2</xref>, <xref rid="liv16137-bib-0004" ref-type="bibr">4</xref>]. However, despite corticosteroid treatment 28&#8208;day mortality is greater than 15%&#8211;20%, but can be as high as 40%, and the survival benefit tends to wane over time [<xref rid="liv16137-bib-0005" ref-type="bibr">5</xref>, <xref rid="liv16137-bib-0006" ref-type="bibr">6</xref>, <xref rid="liv16137-bib-0007" ref-type="bibr">7</xref>]. Moreover, a significant proportion of patients with SAH are not candidates for corticosteroids due to contraindications, like&#8212;uncontrolled infection, gastrointestinal bleeding or acute kidney injury.</p><p>Severe liver inflammation leads to hepatocyte necrosis and along with the systemic inflammatory response impedes liver cell regeneration. While corticosteroids function by attenuating the inflammatory response, an important therapeutic target is augmenting hepatic regeneration. Granulocyte colony&#8208;stimulating factor (G&#8208;CSF) mobilises CD34<sup>+</sup> cells, induces hepatocyte growth factor and stimulates proliferation of hepatocyte progenitor cells [<xref rid="liv16137-bib-0008" ref-type="bibr">8</xref>, <xref rid="liv16137-bib-0009" ref-type="bibr">9</xref>, <xref rid="liv16137-bib-0010" ref-type="bibr">10</xref>]. G&#8208;CSF has demonstrated efficacy in promoting hepatic regeneration in translational studies and has shown promise in clinical trials at improving survival of patients with SAH [<xref rid="liv16137-bib-0009" ref-type="bibr">9</xref>, <xref rid="liv16137-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv16137-bib-0011" ref-type="bibr">11</xref>, <xref rid="liv16137-bib-0012" ref-type="bibr">12</xref>]. However, most of these studies are small scale and are from Asia.</p><p>In a large clinical trial on the use of G&#8208;CSF in patients with acute&#8208;on&#8208;chronic liver failure, Engelman et&#160;al., did not find any significant benefit of G&#8208;CSF over standard medical therapy in improving 90&#8208;day transplant&#8208;free survival [<xref rid="liv16137-bib-0013" ref-type="bibr">13</xref>]. Alcohol&#8208;associated hepatitis comprised about half of all the precipitating events in both the study cohorts. While this is the only well powered study aimed to investigate patients with acute&#8208;on&#8208;chronic liver failure, only one third of the entire G&#8208;CSF arm completed the planned number of doses and the survival data in patients with alcohol&#8208;associated hepatitis is unavailable. Thus, there is inadequate data to support or refute the use of G&#8208;CSF in SAH.</p></sec><sec sec-type="methods" id="liv16137-sec-0008"><label>2</label><title>Methods</title><sec id="liv16137-sec-0009"><label>2.1</label><title>Study Setting and Database</title><p>This is a multicentre retrospective cohort study using a large research network (TriNetX, LLC) comprising over 100 million patients. &#8216;TriNetX is the global federated health research network providing access to electronic medical records (diagnoses, procedures, medications, laboratory values, genomic information) across large healthcare organizations&#8217;. The network research with 89 health&#8208;care organisations was queried on May 2, 2024, and all the 89 health&#8208;care organisations comprising approximately 109 million patients responded. The network research obtains data from electronic health records of individual patients. Longitudinal data on individual patients is available and includes inpatient and outpatient data based on visits&#8212;ambulatory or inpatient encounters. To obtain data from the TriNetX platform, browser&#8208;based real&#8208;time analytical features were used (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://open.trinetx.com/trinetx-publication-guidelines/" ext-link-type="uri">https://open.trinetx.com/trinetx&#8208;publication&#8208;guidelines/</ext-link>). The query was conducted to obtain records of patients who had the index event from January 2016 to November 2023 (Figure&#160;<xref rid="liv16137-fig-0001" ref-type="fig">1</xref>). Where necessary, assistance was obtained from the experts and biostatisticians (TriNetX) in building the queries and running the analysis. Most health&#8208;care organisation are from the United States&#8212;Clinical and Translational Science Awardees and National Cancer Institute&#8211;designated cancer centres. Other centres are from Europe, Asia and South America.</p><fig position="float" fig-type="FIGURE" id="liv16137-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Consort diagram illustrating database search and patient cohort selection strategy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="LIV-45-0-g003.jpg"/></fig></sec><sec id="liv16137-sec-0010"><label>2.2</label><title>Query Criteria and Cohort Definitions</title><p>Individuals &#8805;&#8201;16&#8201;years of age who were diagnosed with alcohol&#8208;associated hepatitis from January 2016 to November 2023 were selected for the study. Patients with alcohol&#8208;associated hepatitis were identified using ICD&#8208;10&#8208;CM code&#160;(<xref rid="liv16137-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>). We used the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria to define alcohol&#8208;associated hepatitis&#8212;presence of alcohol use disorder, serum aspartate aminotransferase &gt;&#8201;50&#8201;U/L but &lt;&#8201;400&#8201;U/L, serum bilirubin &#8805;&#8201;3&#8201;mg/dL and elevated serum bilirubin for &lt;&#8201;8&#8201;weeks [<xref rid="liv16137-bib-0001" ref-type="bibr">1</xref>]. However, the ratio of serum aspartate aminotransferase and alanine aminotransferase at a given time cannot be determined. Mean values of serum albumin, bilirubin, creatinine, international normalised ratio (INR) and platelet count at the time of presentation were obtained.</p><p>Severe alcohol&#8208;associated hepatitis was defined as presence of alcohol&#8208;associated hepatitis along with a serum bilirubin of &gt;&#8201;5&#8201;mg/dL and an INR of 1.5 or more. The laboratory values of serum bilirubin and INR were identified using Logical Observation Identifier Names and Codes. Since we are unable to calculate the model for end&#8208;stage liver disease (MELD) score or Maddrey's discriminant function score in individual patients, we used these stringent criteria (serum bilirubin &#8805;&#8201;5&#8201;mg/dL and INR &#8805;&#8201;1.5) to include only alcohol&#8208;associated hepatitis patients with a Maddrey's discriminant function score of &gt;&#8201;32 (at least 32.6). This corresponds to a MELD score of at least 18. As per the NIAAA recommendations, patients who underwent liver biopsy with exclusion of other aetiologies of acute hepatitis (as defined below) were categorised as &#8216;definite&#8217; alcohol&#8208;associated hepatitis and rest of the patients with alcohol&#8208;associated hepatitis who did not undergo liver biopsy were &#8216;probable&#8217; alcohol&#8208;associated hepatitis [<xref rid="liv16137-bib-0001" ref-type="bibr">1</xref>]. We also explored the database to look for patients with had metabolic dysfunction associated steatohepatitis along with alcohol&#8208;associated hepatitis using ICD&#8208;10 codes.</p><p>Patients with other causes of acute hepatitis or acute liver injury&#8212;acute viral hepatitis, autoimmune hepatitis, drug&#8208;induced liver injury, Wilson, disease, acute hepatic or portal vein thrombosis, biliary obstruction, malignant neoplasms, prothrombotic states, and coumadin use were excluded. Patients with sepsis at the time of inclusion were also excluded.</p></sec><sec id="liv16137-sec-0011"><label>2.3</label><title>Interventions</title><p>Use of medications for the treatment of SAH was identified using Healthcare Common Procedure Coding System and RxNorm (normalised names for all clinical drugs in the United States market). G&#8208;CSF included filgrastim, pegfilgrastim and lenograstim. Corticosteroid group received prednisone, prednisolone, methylprednisolone or dexamethasone. Patients who received corticosteroids were excluded from G&#8208;CSF cohort and patients who received G&#8208;CSF were excluded from the corticosteroid cohort. The mean number (and standard deviation) of G&#8208;CSF doses and corticosteroid doses were calculated in the respective cohorts.</p></sec><sec id="liv16137-sec-0012"><label>2.4</label><title>Follow Up and Clinical Outcomes</title><p>Individuals selected for the study were followed up for a median of 6&#8201;months following the index events (diagnosis of severe alcohol&#8208;associated hepatitis). The index event was defined as the earliest time point after which outcomes are analysed.</p><p>
<italic toggle="yes">Primary outcome</italic>: 90&#8208;day overall survival in G&#8208;CSF group versus corticosteroid group and 90&#8208;day overall survival in G&#8208;CSF group versus standard medical therapy (SMT&#8201;=&#8201;no G&#8208;CSF, corticosteroid or NAC) group.</p><p>
<italic toggle="yes">Secondary outcomes</italic>: 6&#8208;month transplant&#8208;free survival in G&#8208;CSF group compared with corticosteroid group and 6&#8208;month transplant&#8208;free survival in G&#8208;CSF group compared with SMT group. Other outcomes were the rate of gastrointestinal bleeding, bacterial sepsis, hepatic encephalopathy, and acute kidney injury in patients treated with G&#8208;CSF versus those treated with corticosteroids, and G&#8208;CSF group versus SMT group.</p><p>To ensure adequate follow&#8208;up and to minimise loss to follow&#8208;up, individuals were assessed for follow&#8208;up using inpatient and outpatient visits. Propensity score (1:1) matching was performed to control confounding variables. The analyses included outcomes that occurred in the time window that started 1&#8201;day after the first occurrence of the index event and ended 180&#8201;days after the first occurrence of the index event. The index event only includes events that occurred up to 20&#8201;years ago. Patients whose index event occurred 20&#8201;years or more ago are excluded. Since all of them met the criteria for the index event none of the patients in the two cohorts were excluded. The details of index events and outcome criteria are presented in the <xref rid="liv16137-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>.</p></sec><sec id="liv16137-sec-0013"><label>2.5</label><title>Ethical Considerations</title><p>&#8216;The data reviewed in this retrospective study is a secondary analysis of existing data and does not involve intervention or interaction with human subjects and is de&#8208;identified per the de&#8208;identification standard defined in Section &#167;164.514 (a) of the HIPAA Privacy Rule. The process by which the data is de&#8208;identified is attested to through a formal determination by a qualified expert as defined in Section &#167;164.514 (b) (1) of the HIPAA Privacy Rule. This formal determination by a qualified expert refreshed on December 2020&#8217; (Publication Guidelines&#8212;TriNetX) [<xref rid="liv16137-bib-0014" ref-type="bibr">14</xref>] This study involves human subjects; however, the western institutional review board has provided a waiver to TriNetX since it utilises aggregate counts, and investigators do not have access to protected health information from the participating health&#8208;care organisations. Thus, the study is exempt from informed consent. &#8216;To fortify protected health information, TriNetX rounds up the number of patients to the nearest 10 for analytic purposes&#8217;. Specific geographical and institutional data of participating centres are kept anonymous.</p></sec><sec id="liv16137-sec-0014"><label>2.6</label><title>Statistical Analyses</title><p>Mean and standard deviation were calculated for continuous variables, and proportion and percentage were calculated for dichotomous and categorical variables. Age and the comorbidities were also assessed as a proxy for the Charlson comorbidity index since the Charlson comorbidity index of individual patients cannot be calculated in the database (Table&#160;<xref rid="liv16137-tbl-0001" ref-type="table">1</xref>). For clinical outcomes, risk ratio (RR) and risk difference were calculated, and Kaplan&#8211;Meir analysis with survival curve was obtained for median 90&#8208;day overall survival and 180&#8208;day transplant&#8208;free survival. The statistical significance was set at a two&#8208;sided <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. All the statistical analyses were performed using the TriNetX platform.</p><table-wrap position="float" id="liv16137-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline characteristics of patients with severe alcohol&#8208;associated hepatitis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Characteristic name</th><th align="center" colspan="3" valign="bottom" rowspan="1">Before propensity matching</th><th align="center" colspan="3" valign="bottom" rowspan="1">After propensity matching</th><th align="center" colspan="3" valign="bottom" rowspan="1">Before propensity matching</th><th align="center" colspan="3" valign="bottom" rowspan="1">After propensity matching</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">G&#8208;CSF (<italic toggle="yes">N</italic>&#8201;=&#8201;224)</th><th align="center" valign="bottom" rowspan="1" colspan="1">SMT (<italic toggle="yes">N</italic>&#8201;=&#8201;8573)</th><th align="center" valign="bottom" rowspan="1" colspan="1">SMD</th><th align="center" valign="bottom" rowspan="1" colspan="1">G&#8208;CSF (<italic toggle="yes">N</italic>&#8201;=&#8201;223)</th><th align="center" valign="bottom" rowspan="1" colspan="1">SMT (<italic toggle="yes">N</italic>&#8201;=&#8201;223)</th><th align="center" valign="bottom" rowspan="1" colspan="1">SMD</th><th align="center" valign="bottom" rowspan="1" colspan="1">G&#8208;CSF (<italic toggle="yes">N</italic>&#8201;=&#8201;224)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Corticosteroid (<italic toggle="yes">N</italic>&#8201;=&#8201;10&#8201;800)</th><th align="center" valign="bottom" rowspan="1" colspan="1">SMD</th><th align="center" valign="bottom" rowspan="1" colspan="1">G&#8208;CSF (<italic toggle="yes">N</italic>&#8201;=&#8201;224)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Corticosteroid (<italic toggle="yes">N</italic>&#8201;=&#8201;224)</th><th align="center" valign="bottom" rowspan="1" colspan="1">SMD</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="13" valign="top" rowspan="1">Demographics</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean age +/&#8722;SD (years)</td><td align="center" valign="top" rowspan="1" colspan="1">47.22&#8201;&#177;&#8201;11.33</td><td align="center" valign="top" rowspan="1" colspan="1">48.4&#8201;&#177;&#8201;11.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.12</td><td align="center" valign="top" rowspan="1" colspan="1">47.22&#8201;&#177;&#8201;11.33</td><td align="center" valign="top" rowspan="1" colspan="1">47.34&#8201;&#177;&#8201;10.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td><td align="center" valign="top" rowspan="1" colspan="1">47.22&#8201;&#177;&#8201;11.33</td><td align="center" valign="top" rowspan="1" colspan="1">46.71&#8201;&#177;&#8201;11.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">47.22&#8201;&#177;&#8201;11.33</td><td align="center" valign="top" rowspan="1" colspan="1">46.8&#8201;&#177;&#8201;11.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">86 (36.44%)</td><td align="center" valign="top" rowspan="1" colspan="1">3428 (37.70%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">86 (36.44%)</td><td align="center" valign="top" rowspan="1" colspan="1">80 (36.20)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">86 (36.44%)</td><td align="center" valign="top" rowspan="1" colspan="1">4888 (37.46%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">86 (36.44%)</td><td align="center" valign="top" rowspan="1" colspan="1">88 (37.29%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">180 (76.27%)</td><td align="center" valign="top" rowspan="1" colspan="1">(70.34%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">174 (78.73%)</td><td align="center" valign="top" rowspan="1" colspan="1">174 (78.73%)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">180 (76.27%)</td><td align="center" valign="top" rowspan="1" colspan="1">9265 (71.01%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td><td align="center" valign="top" rowspan="1" colspan="1">180 (76.27%)</td><td align="center" valign="top" rowspan="1" colspan="1">191 (80.93%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hispanic or Latino</td><td align="center" valign="top" rowspan="1" colspan="1">18 (7.62%)</td><td align="center" valign="top" rowspan="1" colspan="1">1017 (11.19%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">18 (7.62%)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (9.96%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td><td align="center" valign="top" rowspan="1" colspan="1">18 (7.62%)</td><td align="center" valign="top" rowspan="1" colspan="1">1344 (10.30%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">18 (7.62%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (8.48%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">African American</td><td align="center" valign="top" rowspan="1" colspan="1">10 (4.23%)</td><td align="center" valign="top" rowspan="1" colspan="1">768 (8.45%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td><td align="center" valign="top" rowspan="1" colspan="1">10 (4.23%)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (6.33%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td><td align="center" valign="top" rowspan="1" colspan="1">10 (4.23%)</td><td align="center" valign="top" rowspan="1" colspan="1">1071 (8.21%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td><td align="center" valign="top" rowspan="1" colspan="1">10 (4.23%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (4.24%)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="13" valign="top" rowspan="1">Mean lab values (blood/serum)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Creatinine&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">1.73&#8201;&#177;&#8201;1.54</td><td align="center" valign="top" rowspan="1" colspan="1">1.10&#8201;&#177;&#8201;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.54</td><td align="center" valign="top" rowspan="1" colspan="1">1.74&#8201;&#177;&#8201;1.45</td><td align="center" valign="top" rowspan="1" colspan="1">1.68&#8201;&#177;&#8201;1.09</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td><td align="center" valign="top" rowspan="1" colspan="1">1.73&#8201;&#177;&#8201;1.54</td><td align="center" valign="top" rowspan="1" colspan="1">1.35&#8201;&#177;&#8201;1.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1">1.74&#8201;&#177;&#8201;1.56</td><td align="center" valign="top" rowspan="1" colspan="1">1.53&#8201;&#177;&#8201;1.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Albumin&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">3.19&#8201;&#177;&#8201;0.72</td><td align="center" valign="top" rowspan="1" colspan="1">2.93&#8201;&#177;&#8201;0.77</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">3.20&#8201;&#177;&#8201;0.74</td><td align="center" valign="top" rowspan="1" colspan="1">2.97&#8201;&#177;&#8201;0.71</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">3.12&#8201;&#177;&#8201;0.72</td><td align="center" valign="top" rowspan="1" colspan="1">2.82&#8201;&#177;&#8201;0.65</td><td align="center" valign="top" rowspan="1" colspan="1">0.72</td><td align="center" valign="top" rowspan="1" colspan="1">3.12&#8201;&#177;&#8201;0.72</td><td align="center" valign="top" rowspan="1" colspan="1">2.99&#8201;&#177;&#8201;0.68</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Total Bilirubin&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">7.16&#8201;&#177;&#8201;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">8.14&#8201;&#177;&#8201;4.28</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">7.16&#8201;&#177;&#8201;3.94</td><td align="center" valign="top" rowspan="1" colspan="1">7.99&#177;</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td><td align="center" valign="top" rowspan="1" colspan="1">7.16&#8201;&#177;&#8201;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">9.60&#8201;&#177;&#8201;3.94</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td><td align="center" valign="top" rowspan="1" colspan="1">6.94&#8201;&#177;&#8201;4.56</td><td align="center" valign="top" rowspan="1" colspan="1">7.85&#8201;&#177;&#8201;5.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">INR&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">1.89&#8201;&#177;&#8201;0.68</td><td align="center" valign="top" rowspan="1" colspan="1">1.73&#8201;&#177;&#8201;0.41</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1">1.89&#8201;&#177;&#8201;0.54</td><td align="center" valign="top" rowspan="1" colspan="1">1.84&#8201;&#177;&#8201;0.43</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">1.89&#8201;&#177;&#8201;0.68</td><td align="center" valign="top" rowspan="1" colspan="1">2.11&#8201;&#177;&#8201;1.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.41</td><td align="center" valign="top" rowspan="1" colspan="1">1.92&#8201;&#177;&#8201;0.73</td><td align="center" valign="top" rowspan="1" colspan="1">2.07&#8201;&#177;&#8201;0.90</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Platelet count&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">142&#8201;&#177;&#8201;111</td><td align="center" valign="top" rowspan="1" colspan="1">138&#8201;&#177;&#8201;97</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td><td align="center" valign="top" rowspan="1" colspan="1">143&#8201;&#177;&#8201;111</td><td align="center" valign="top" rowspan="1" colspan="1">141&#8201;&#177;&#8201;106</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">142&#8201;&#177;&#8201;111</td><td align="center" valign="top" rowspan="1" colspan="1">129&#8201;&#177;&#8201;88</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">143&#8201;&#177;&#8201;112</td><td align="center" valign="top" rowspan="1" colspan="1">135&#8201;&#177;&#8201;96.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" colspan="13" valign="top" rowspan="1">Comorbidities</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cirrhosis of liver</td><td align="center" valign="top" rowspan="1" colspan="1">205 (86.86%)</td><td align="center" valign="top" rowspan="1" colspan="1">4225 (46.47%)</td><td align="center" valign="top" rowspan="1" colspan="1">1.11</td><td align="center" valign="top" rowspan="1" colspan="1">203 (91.03%)</td><td align="center" valign="top" rowspan="1" colspan="1">204 (91.48%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">205 (86.86%)</td><td align="center" valign="top" rowspan="1" colspan="1">150 (63.56%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.56</td><td align="center" valign="top" rowspan="1" colspan="1">205 (86.86%)</td><td align="center" valign="top" rowspan="1" colspan="1">203 (86.02%)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic kidney disease</td><td align="center" valign="top" rowspan="1" colspan="1">112 (47.46%)</td><td align="center" valign="top" rowspan="1" colspan="1">755 (8.30%)</td><td align="center" valign="top" rowspan="1" colspan="1">1.28</td><td align="center" valign="top" rowspan="1" colspan="1">112 (50.22%)</td><td align="center" valign="top" rowspan="1" colspan="1">115 (51.57%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">112 (47.46%)</td><td align="center" valign="top" rowspan="1" colspan="1">1244 (9.53%)</td><td align="center" valign="top" rowspan="1" colspan="1">1.03</td><td align="center" valign="top" rowspan="1" colspan="1">112 (47.46%)</td><td align="center" valign="top" rowspan="1" colspan="1">120 (50.85%)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Overweight and obesity</td><td align="center" valign="top" rowspan="1" colspan="1">76 (33.93%)</td><td align="center" valign="top" rowspan="1" colspan="1">1359 (14.95%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.56</td><td align="center" valign="top" rowspan="1" colspan="1">75 (36.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">79 (35.43%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">76 (33.93%)</td><td align="center" valign="top" rowspan="1" colspan="1">2571 (19.70%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1">76 (32.20%)</td><td align="center" valign="top" rowspan="1" colspan="1">78 (33.05%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" valign="top" rowspan="1" colspan="1">71 (30.08%)</td><td align="center" valign="top" rowspan="1" colspan="1">1149 (12.64%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.52</td><td align="center" valign="top" rowspan="1" colspan="1">71 (31.84%)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (31.84%)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">71 (30.08%)</td><td align="center" valign="top" rowspan="1" colspan="1">1708 (13.09%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td><td align="center" valign="top" rowspan="1" colspan="1">71 (30.08%)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (27.97%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ischemic heart diseases</td><td align="center" valign="top" rowspan="1" colspan="1">48 (20.34%)</td><td align="center" valign="top" rowspan="1" colspan="1">892 (9.81%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.46</td><td align="center" valign="top" rowspan="1" colspan="1">48 (21.52%)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (20.18%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">48 (20.34%)</td><td align="center" valign="top" rowspan="1" colspan="1">1312 (10.05%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">48 (20.34%)</td><td align="center" valign="top" rowspan="1" colspan="1">55 (23.31%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic respiratory diseases</td><td align="center" valign="top" rowspan="1" colspan="1">38 (16.10%)</td><td align="center" valign="top" rowspan="1" colspan="1">1202 (13.22%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">38 (17.04%)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (16.14%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td><td align="center" valign="top" rowspan="1" colspan="1">38 (16.10%)</td><td align="center" valign="top" rowspan="1" colspan="1">2201 (16.87%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">38 (16.10%)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (16.53%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heart failure</td><td align="center" valign="top" rowspan="1" colspan="1">34 (14.41%)</td><td align="center" valign="top" rowspan="1" colspan="1">693 (17.49%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.30</td><td align="center" valign="top" rowspan="1" colspan="1">34 (15.25%)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (15.70%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">34 (14.41%)</td><td align="center" valign="top" rowspan="1" colspan="1">1069 (8.19%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.23</td><td align="center" valign="top" rowspan="1" colspan="1">34 (14.41%)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (14.41%)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td></tr></tbody></table><table-wrap-foot id="liv16137-ntgp-0002"><fn id="liv16137-note-0002"><p>Abbreviations: G&#8208;CSF, granulocyte colony&#8208;stimulating factor; <italic toggle="yes">N</italic>, number of patients in each cohort; SD, standard deviation; SMT, standard medical treatment; SMD, standard mean difference.</p></fn></table-wrap-foot></table-wrap></sec><sec id="liv16137-sec-0015"><label>2.7</label><title>Sensitivity Analysis</title><p>Propensity score matching was performed. To generate a propensity score, the first step was logistic regression (where the outcome was exposure). Then factors associated with the exposure were determined by evaluating Table&#160;<xref rid="liv16137-tbl-0001" ref-type="table">1</xref> (before matching) for variables significantly different between the study and control groups. Propensity score matching was performed to reduce bias in estimating treatment effects and to reduce the likelihood of confounding when analysing non&#8208;randomised data. Propensity score matching was based on relevant covariates using greedy nearest neighbour algorithms&#8212;matching study and control groups with the highest propensity scores. Characteristics with standard mean difference between cohorts &lt;&#8201;0.1 were considered well matched. Characteristics of the cohorts before and after matching are summarised in Table&#160;<xref rid="liv16137-tbl-0001" ref-type="table">1</xref>.</p></sec><sec id="liv16137-sec-0016"><label>2.8</label><title>Survival Analysis</title><p>Kaplan&#8211;Meier analysis was performed on propensity&#8208;matched groups. Kaplan&#8211;Meier analysis was used to estimate the probability of an outcome at a respective time interval (daily time interval was used in the analysis). To account for the patients who exited the cohort during the analysis period censoring is applied. In this analysis, patients are removed from the analysis (censored) after the last fact in their record. Censoring was applied to account for the patients who exited the cohort during the analysis period to avoid inclusion in the analysis. The output summary includes: Patients in each cohort (count of patients meeting query criteria); Patients with outcome (of the patients in the cohort, count of patients that had the outcome in the time window); Median survival (the number of days when the survival drops below 50% during the time window); and survival probability at end of time window (the % survival at the end of the time window). Log&#8208;rank testing was performed to assess statistical differences in time to event for each cohort. Hazard ratios (HR) were calculated using a univariate Cox&#8208;proportional model. Cox&#8208;proportional hazards model assumes that the chance of each hazard remains similar over time. Analyses were performed at 28, 90 and 180&#8201;days for key outcomes.</p></sec></sec><sec sec-type="results" id="liv16137-sec-0017"><label>3</label><title>Results</title><p>We identified 82&#8201;187 patients with alcohol&#8208;associated hepatitis and 20&#8201;132 (24.50%) out of them met criteria for severe alcohol&#8208;associated hepatitis. Most of the patients were from the United States (~98%, <xref rid="liv16137-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>). Eighty percent of patients completed a six&#8208;month follow&#8208;up. More than half of all patients with severe alcohol&#8208;associated hepatitis (53.65%, <italic toggle="yes">N</italic>&#8201;=&#8201;10&#8201;800) were treated with corticosteroids and 224 (1.11%) received G&#8208;CSF for at least 5&#8201;days, and 8573 (42.58%) did not receive corticosteroids, G&#8208;CSF or N&#8208;acetyl cysteine. A total of 1198 (5.95%) patients with alcohol&#8208;associated hepatitis had definite SAH based on liver biopsy. Patients who received G&#8208;CSF were younger (45.5 vs. 48.4&#8201;years, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002) White (79.91% vs. 72.40%) and had more comorbidities (Table&#160;<xref rid="liv16137-tbl-0001" ref-type="table">1</xref>). There was no difference in age or gender between G&#8208;CSF and corticosteroid groups; however, the White population received G&#8208;CSF more commonly than corticosteroids (80% vs. 73%). Mean values of serum creatinine, bilirubin, and INR at the time of clinical presentation were higher in the G&#8208;CSF cohort before propensity matching. Patients with comorbid conditions were more likely to receive G&#8208;CSF than corticosteroids. The mean number of G&#8208;CSF doses was 8.91 (&#177;3.2).</p><sec id="liv16137-sec-0018"><label>3.1</label><title>Primary Outcomes</title><p>Ninety&#8208;day overall survival was significantly higher in the G&#8208;CSF cohort compared with SMT (88.31% vs. 62.36%, HR 0.26, 95% CI 0.17&#8211;0.41) (Figure&#160;<xref rid="liv16137-fig-0002" ref-type="fig">2</xref>). More patients in the G&#8208;CSF group survived for 90&#8201;days compared with the corticosteroid group (88.31% vs. 74.39%, HR 0.38, 95% CI 0.23&#8211;0.62) (Figure&#160;<xref rid="liv16137-fig-0002" ref-type="fig">2b</xref>).</p><fig position="float" fig-type="FIGURE" id="liv16137-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>(a) Kaplan&#8211;Meier graph for 90&#8208;day overall survival G&#8208;CSF versus standard medical therapy in patients with severe alcohol&#8208;associated hepatitis. (b) Kaplan&#8211;Meier graph for 90&#8208;day overall survival G&#8208;CSF versus Corticosteroid. SAH_G&#8208;CSF severe alcohol&#8208;associated hepatitis treated with granulocyte colony&#8208;stimulating factor (G&#8208;CSF), SAH_SMT, severe alcohol&#8208;associated hepatitis treated with standard medical therapy, SAH_CS, severe alcohol&#8208;associated hepatitis treated with corticosteroid, df, degree of freedom.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="LIV-45-0-g002.jpg"/></fig></sec><sec id="liv16137-sec-0019"><label>3.2</label><title>Secondary Outcomes</title><p>Six&#8208;month transplant&#8208;free survival was better in the G&#8208;CSF group compared with SMT group (83.53% vs. 55.36%, HR 0.30, 95% CI 0.20&#8211;0.44), and corticosteroid groups (83.53% vs. 68.15%, HR 0.40, 95% CI 0.26&#8211;0.60) (Figure&#160;<xref rid="liv16137-fig-0003" ref-type="fig">3a,b</xref>). Gastrointestinal bleeding was seen less commonly in patients who received G&#8208;CSF compared with SMT (5.02% vs. 14.55%, RR 0.34, 95% CI 0.18&#8211;0.66) and corticosteroids (5.02% vs. 13.67%, RR 0.48, 95% CI 0.16&#8211;0.62). Bacterial sepsis (21.70% vs. 17.93%, RR 1.21, 95% CI 0.82&#8211;1.78), acute kidney injury (43.39% vs. 39.62%, RR 1.09, 95% CI 0.87&#8211;1.37), and hepatic encephalopathy (10.85% vs. 15.57%, RR 0.70, 95% CI 0.42&#8211;1.15) were observed at similar rates in patients treated with G&#8208;CSF and SMT (Table&#160;<xref rid="liv16137-tbl-0002" ref-type="table">2</xref>). Hepatic encephalopathy was observed more commonly in the corticosteroid group (20.09% vs. 10.85%) compared with G&#8208;CSF group (RR 0.55, 95% CI 0.34&#8211;0.87). Bacterial sepsis (22.32% vs. 23.66%) and acute kidney injury (44.29% vs. 53.43%) were observed at similar rates in G&#8208;CSF and corticosteroid groups (Table&#160;<xref rid="liv16137-tbl-0003" ref-type="table">3</xref>).</p><fig position="float" fig-type="FIGURE" id="liv16137-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>(a) Kaplan&#8211;Meier graph for 6&#8208;month transplant&#8208;free survival G&#8208;CSF versus SMT. (b) Kaplan&#8211;Meier graph for 6&#8208;month transplant&#8208;free survival G&#8208;CSF versus Corticosteroid. SAH_G&#8208;CSF severe alcohol&#8208;associated hepatitis treated with granulocyte colony&#8208;stimulating factor (G&#8208;CSF), SAH_SMT, severe alcohol&#8208;associated hepatitis treated with standard medical therapy, SAH_CS, severe alcohol&#8208;associated hepatitis treated with corticosteroid, df, degree of freedom.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="LIV-45-0-g001.jpg"/></fig><table-wrap position="float" id="liv16137-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Secondary outcomes in severe alcohol&#8208;associated hepatitis patients treated with G&#8208;CSF and standard medical therapy after propensity score matching.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Clinical outcomes</th><th align="center" colspan="2" valign="bottom" rowspan="1">Number (%) with outcome</th><th align="center" rowspan="2" valign="bottom" colspan="1">Risk ratio</th><th align="center" rowspan="2" valign="bottom" colspan="1">95% CI</th><th align="center" rowspan="2" valign="bottom" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">G&#8208;CSF (<italic toggle="yes">N</italic>&#8201;=&#8201;220)</th><th align="center" valign="bottom" rowspan="1" colspan="1">SMT (<italic toggle="yes">N</italic>&#8201;=&#8201;220)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">6&#8208;month transplant&#8208;free survival</td><td align="center" valign="top" rowspan="1" colspan="1">185 (83.53%)</td><td align="center" valign="top" rowspan="1" colspan="1">127 (55.36%)</td><td align="center" valign="top" rowspan="1" colspan="1">HR&#8201;=&#8201;0.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.20&#8211;0.44</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GI bleeding</td><td align="center" valign="top" rowspan="1" colspan="1">11 (5.02%)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (14.55%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.18&#8211;0.66</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Acute kidney injury</td><td align="center" valign="top" rowspan="1" colspan="1">97 (43.39%)</td><td align="center" valign="top" rowspan="1" colspan="1">89 (39.62%)</td><td align="center" valign="top" rowspan="1" colspan="1">1.09</td><td align="center" valign="top" rowspan="1" colspan="1">0.87&#8211;1.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bacterial sepsis</td><td align="center" valign="top" rowspan="1" colspan="1">46 (20.53%)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (17.93%)</td><td align="center" valign="top" rowspan="1" colspan="1">1.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.82&#8211;1.78</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatic encephalopathy</td><td align="center" valign="top" rowspan="1" colspan="1">24 (10.85%)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (15.57%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.70</td><td align="center" valign="top" rowspan="1" colspan="1">0.42&#8211;1.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td></tr></tbody></table><table-wrap-foot id="liv16137-ntgp-0003"><fn id="liv16137-note-0003"><p>Abbreviations: CI, confidence interval; G&#8208;CSF, granulocyte colony&#8208;stimulating factor; GI, gastrointestinal; HR, hazard ratio; SMT, standard medical therapy.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="liv16137-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Secondary outcomes in severe alcohol&#8208;associated hepatitis patients treated with G&#8208;CSF and corticosteroids after propensity score matching.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Clinical outcomes</th><th align="center" colspan="2" valign="bottom" rowspan="1">Number (%) with outcome</th><th align="center" rowspan="2" valign="bottom" colspan="1">Risk ratio</th><th align="center" rowspan="2" valign="bottom" colspan="1">95% CI</th><th align="center" rowspan="2" valign="bottom" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">G&#8208;CSF (<italic toggle="yes">N</italic>&#8201;=&#8201;224)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Corticosteroid (<italic toggle="yes">N</italic>&#8201;=&#8201;224)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">6&#8208;month transplant&#8208;free survival</td><td align="center" valign="top" rowspan="1" colspan="1">187 (82.89%)</td><td align="center" valign="top" rowspan="1" colspan="1">139 (60.21%)</td><td align="center" valign="top" rowspan="1" colspan="1">HR&#8201;=&#8201;0.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.26&#8211;0.60</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GI bleeding</td><td align="center" valign="top" rowspan="1" colspan="1">11 (5.02%)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (13.67%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td><td align="center" valign="top" rowspan="1" colspan="1">0.16&#8211;0.62</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Acute kidney injury</td><td align="center" valign="top" rowspan="1" colspan="1">97 (43.39%)</td><td align="center" valign="top" rowspan="1" colspan="1">4099 (31.03%)</td><td align="center" valign="top" rowspan="1" colspan="1">1.35</td><td align="center" valign="top" rowspan="1" colspan="1">1.16&#8211;1.57</td><td align="center" valign="top" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bacterial sepsis</td><td align="center" valign="top" rowspan="1" colspan="1">46 (20.53%)</td><td align="center" valign="top" rowspan="1" colspan="1">49 (21.43%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.84</td><td align="center" valign="top" rowspan="1" colspan="1">0.55&#8211;1.28</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatic encephalopathy</td><td align="center" valign="top" rowspan="1" colspan="1">24 (10.85%)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (10.28%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.61</td><td align="center" valign="top" rowspan="1" colspan="1">0.23&#8211;1.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.54</td></tr></tbody></table><table-wrap-foot id="liv16137-ntgp-0004"><fn id="liv16137-note-0004"><p>Abbreviations: CI, confidence interval; G&#8208;CSF, granulocyte colony&#8208;stimulating factor; GI, gastrointestinal; HR, hazard ratio.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="liv16137-sec-0020"><label>4</label><title>Discussion</title><p>Current guidelines recommend treatment of SAH with corticosteroids in the absence of contraindications [<xref rid="liv16137-bib-0001" ref-type="bibr">1</xref>, <xref rid="liv16137-bib-0015" ref-type="bibr">15</xref>]. However, overall short&#8208;term survival is poor in patients who are excluded from corticosteroid therapy due to contraindications or failure to respond to such therapy. One of the alternatives to corticosteroids studied in the treatment of SAH is G&#8208;CSF. Multiple prospective studies from India have shown improvement in 1&#8208; to 3&#8208;month survival [<xref rid="liv16137-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv16137-bib-0011" ref-type="bibr">11</xref>, <xref rid="liv16137-bib-0012" ref-type="bibr">12</xref>, <xref rid="liv16137-bib-0016" ref-type="bibr">16</xref>]. Nonetheless, these studies are small scale with cumulative number of patients treated with G&#8208;CSF in these trials is about 100. Engelmann et&#160;al., in a multicentre randomised trial of G&#8208;CSF in acute&#8208;on&#8208;chronic liver failure (GRAFT study), did not find a survival advantage of G&#8208;CSF over standard therapy alone [<xref rid="liv16137-bib-0013" ref-type="bibr">13</xref>]. Alcohol&#8208;associated hepatitis comprised about half of the precipitating events in each cohort (<italic toggle="yes">N</italic>&#8201;=&#8201;55 in G&#8208;CSF group). These results do not support the use of G&#8208;CSF in SAH.</p><p>To the best of our knowledge, we provide the largest data, albeit retrospective, on the use of G&#8208;CSF to treat SAH. Our results indicate that corticosteroids remain the primary treatment of choice for severe alcohol&#8208;associated hepatitis, and the use of G&#8208;CSF remains limited. The limited use of G&#8208;CSF reflects lack of clear data. In an age&#8208;, gender&#8208; and comorbidity&#8208;matched cohort of patients, we observed a significant improvement in 90&#8208;day overall survival of SAH patients treated G&#8208;CSF compared with standard medical therapy (HR&#8201;=&#8201;0.26) and corticosteroids (HR&#8201;=&#8201;0.38). Our findings are in line with most of the previously published studies which have demonstrated a 90&#8208;day survival advantage of G&#8208;CSF compared with SMT [<xref rid="liv16137-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv16137-bib-0011" ref-type="bibr">11</xref>, <xref rid="liv16137-bib-0012" ref-type="bibr">12</xref>]. However, the positive result in Asian studies is limited by small sample size. While the GRAFT study is the largest multicentre randomised trial from the West, it has several limitations [<xref rid="liv16137-bib-0013" ref-type="bibr">13</xref>]. The authors primarily studied acute&#8208;on&#8208;chronic liver failure and do not provide subgroup analysis of patients with each precipitating factor. Only 33% of patients completed all the planned doses of G&#8208;CSF in the intervention group, and we do not know how many of them had alcohol&#8208;associated hepatitis. Many patients had more than one precipitating event. Furthermore, about half of the patients had active infection at the time randomisation and bacterial infection was the precipitating event in about 40% of the G&#8208;CSF arm. Thus, we cannot extrapolate the results of this study to the SAH population.</p><p>There is no published study comparing G&#8208;CSF and corticosteroid therapy. Thus, despite the retrospective study design, we present novel findings of non&#8208;inferior overall survival in G&#8208;CSF treated patients compared with corticosteroids. Furthermore, we found a significant improvement in 6&#8208;month transplant&#8208;free survival among patients who were treated with G&#8208;CSF compared with standard medical therapy (HR&#8201;=&#8201;0.30) or corticosteroid (HR&#8201;=&#8201;0.36). The data on transplant&#8208;free survival in patients treated with G&#8208;CSF is limited.</p><p>Previous studies evaluating the role of G&#8208;CSF in SAH are almost exclusively from Asia (India) and there is lack of robust data in White population. A meta&#8208;analysis by Marot et&#160;al. showed conflicting survival outcomes between the Asian and European countries [<xref rid="liv16137-bib-0017" ref-type="bibr">17</xref>]. In the meta&#8208;analysis, the results from Asian studies showed that G&#8208;CSF was associated with a better survival while the European studies found no difference in survival. We performed a propensity&#8208;matched analysis of patients from all geographic areas in the United States. About 80% (<italic toggle="yes">N</italic>&#8201;=&#8201;180) of patients treated with G&#8208;CSF were Whites, which is the largest representation of White population treated with G&#8208;CSF for this indication. The largest published data in White population is by Engleman et&#160;al.; however, the study does not provide direct evidence to refute use of G&#8208;CSF in SAH per se [<xref rid="liv16137-bib-0013" ref-type="bibr">13</xref>].</p><p>We found a lower rate of gastrointestinal bleeding in patients treated with G&#8208;CSF; however, bacterial sepsis, hepatic encephalopathy, acute kidney injury and hepatorenal syndrome were seen at similar rates across both the groups [G&#8208;CSF versus SMT]. This is an interesting finding and contrasts with most of the Asian studies which have shown lower rate of sepsis in patients who received G&#8208;CSF [<xref rid="liv16137-bib-0011" ref-type="bibr">11</xref>, <xref rid="liv16137-bib-0012" ref-type="bibr">12</xref>, <xref rid="liv16137-bib-0016" ref-type="bibr">16</xref>]. In contrast, the GRAFT study did not show any difference in bacterial infections between G&#8208;CSF and SMT arms; however, more than half of the patients in each cohort had infections at baseline [<xref rid="liv16137-bib-0013" ref-type="bibr">13</xref>]. In a randomised controlled trial by Tayek et&#160;al., patients with SAH who received standard of care treatment versus pegfilgrastim also showed similar incidences of adverse outcomes (sepsis, hepatic encephalopathy, acute kidney injury and hepatorenal syndrome) among the two groups. However, the study did not find an improvement in survival at 90&#8201;days in the G&#8208;CSF group [<xref rid="liv16137-bib-0018" ref-type="bibr">18</xref>]. Another noteworthy finding in our study was that patients treated with G&#8208;CSF had more comorbidities than reported by Asian studies [<xref rid="liv16137-bib-0011" ref-type="bibr">11</xref>, <xref rid="liv16137-bib-0016" ref-type="bibr">16</xref>]. However, it is important to note that patients in our study were older, and the Western population (specially, the US population) is known to have more comorbidities. Furthermore, compared with SMT and corticosteroid groups the G&#8208;CSF group had more comorbidities. This probably represents selection of sicker patients to G&#8208;CSF treatment. By performing propensity matching for comorbidities, we reduced the risk of this potential selection bias.</p><sec id="liv16137-sec-0021"><label>4.1</label><title>Strengths and Limitations</title><p>With the inclusion of 89 health&#8208;care organisations from various geographic regions within the US with access to over 100 million patient health records, our results are generalisable and applicable to the US population. Despite being retrospective, the cohort study design tends to reduce the risk of selection bias. The study also provides an unbiased comparison of overall survival in SAH patients. Additionally, propensity score matching reduces the probability of confounding and may provide a useful approximation of the likely effect of G&#8208;CSF and corticosteroid treatment in patients with SAH.</p><p>Our study has some notable limitations. The retrospective study design is associated with risk of bias. While the database utilises electronic health records for research purposes, detailed clinical data of individual patients is unavailable due to lack of access to protected health information. The diagnosis of SAH is based on ICD 10 code and laboratory values (serum bilirubin and INR). Response to corticosteroid therapy using Lille score could not be performed in individual patients. Our clinical outcomes are overall and transplant&#8208;free survival. The database does not provide information on the dose of G&#8208;CSF; however, patients received a mean of about seven doses of G&#8208;CSF. The database does not provide information about return to alcohol use and alcohol relapse rate, and this can affect the 90&#8208;day and 6&#8208;month survival endpoints. TriNetX performs extensive data quality assessment to reduce the risk associated with data collection. However, as with any other database, conversion of patient's clinical data into codes can result in errors. Unadjusted confounding may exist despite matching if unmeasured factors influenced treatment selection. The database does not provide information on the cause of death. Potential loss of patients can occur due to transfer from one health&#8208;care organisation to another; however, over 80% of patients completed 6&#8201;months of follow&#8208;up.</p><p>In summary, our results demonstrate that G&#8208;CSF is non&#8208;inferior to corticosteroids in the treatment of severe alcohol&#8208;associated hepatitis. However, its use remains controversial and has not yet received widespread endorsement from the global hepatology community. Published data from the West is limited and shade doubts on the benefit of G&#8208;CSF for this indication. Nonetheless, our study stands as one of the largest multicentric studies till date and shows that sun is not down yet for the role of G&#8208;CSF in severe alcohol&#8208;associated hepatitis. Multicenter prospective head&#8208;to&#8208;head studies comparing corticosteroids and G&#8208;CSF can underpin the role of G&#8208;CSF as one of the first&#8208;line treatment options for severe alcohol&#8208;associated hepatitis&#8212;hopefully providing the window of opportunity for these patients to recover and preclude liver transplantation.</p></sec></sec><sec id="liv16137-sec-0023"><title>Ethics Statement</title><p>This has been provided in Section&#160;<xref rid="liv16137-sec-0008" ref-type="sec">2</xref>.</p></sec><sec sec-type="conclusions" id="liv16137-sec-0025"><title>Consent</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="liv16137-sec-0024"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="liv16137-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="LIV-45-0-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="liv16137-sec-0022"><title>Acknowledgements</title><p>We acknowledge the Johns Hopkins University Welch Medical library for providing data resources and software. We would like to acknowledge the technical team at TriNetX for providing analytical support and answering statistical questions.</p></ack><sec sec-type="data-availability" id="liv16137-sec-0027"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="liv16137-bibl-0001"><title>References</title><ref id="liv16137-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="liv16137-cit-0001"><string-name name-style="western"><given-names>D. W.</given-names><surname>Crabb</surname></string-name>, <string-name name-style="western"><given-names>G. Y.</given-names><surname>Im</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Szabo</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Mellinger</surname></string-name>, and <string-name name-style="western"><given-names>M. R.</given-names><surname>Lucey</surname></string-name>, &#8220;<article-title>Diagnosis and Treatment of Alcohol&#8208;Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases</article-title>,&#8221; <source>Hepatology</source><volume>71</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>306</fpage>&#8211;<lpage>333</lpage>, <pub-id pub-id-type="doi">10.1002/hep.30866</pub-id>.<pub-id pub-id-type="pmid">31314133</pub-id></mixed-citation></ref><ref id="liv16137-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="liv16137-cit-0002"><string-name name-style="western"><given-names>P.</given-names><surname>Mathurin</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>O'Grady</surname></string-name>, <string-name name-style="western"><given-names>R. L.</given-names><surname>Carithers</surname></string-name>, et&#160;al., &#8220;<article-title>Corticosteroids Improve Short&#8208;Term Survival in Patients With Severe Alcohol&#8208;Associated Hepatitis: Meta&#8208;Analysis of Individual Patient Data</article-title>,&#8221; <source>Gut</source><volume>60</volume>, no. <issue>2</issue> (<year>2011</year>): <fpage>255</fpage>&#8211;<lpage>260</lpage>, <pub-id pub-id-type="doi">10.1136/gut.2010.224097</pub-id>.<pub-id pub-id-type="pmid">20940288</pub-id></mixed-citation></ref><ref id="liv16137-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="liv16137-cit-0003"><string-name name-style="western"><given-names>E. H.</given-names><surname>Forrest</surname></string-name>, <string-name name-style="western"><given-names>C. D.</given-names><surname>Evans</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Stewart</surname></string-name>, et&#160;al., &#8220;<article-title>Analysis of Factors Predictive of Mortality in Alcohol&#8208;Associated Hepatitis and Derivation and Validation of the Glasgow Alcohol&#8208;Associated Hepatitis Score</article-title>,&#8221; <source>Gut</source><volume>54</volume>, no. <issue>8</issue> (<year>2005</year>): <fpage>1174</fpage>&#8211;<lpage>1179</lpage>, <pub-id pub-id-type="doi">10.1136/gut.2004.050781</pub-id>.<pub-id pub-id-type="pmid">16009691</pub-id><pub-id pub-id-type="pmcid">PMC1774903</pub-id></mixed-citation></ref><ref id="liv16137-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="liv16137-cit-0004"><string-name name-style="western"><given-names>M. J.</given-names><surname>Ramond</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Poynard</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Rueff</surname></string-name>, et&#160;al., &#8220;<article-title>A Randomized Trial of Prednisolone in Patients With Severe Alcohol&#8208;Associated Hepatitis</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>326</volume>, no. <issue>8</issue> (<year>1992</year>): <fpage>507</fpage>&#8211;<lpage>512</lpage>, <pub-id pub-id-type="doi">10.1056/nejm199202203260802</pub-id>.<pub-id pub-id-type="pmid">1531090</pub-id></mixed-citation></ref><ref id="liv16137-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="liv16137-cit-0005"><string-name name-style="western"><given-names>A.</given-names><surname>Louvet</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Thursz</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Kim</surname></string-name>, et&#160;al., &#8220;<article-title>Corticosteroids Reduce Risk of Death Within 28&#8201;Days for Patients With Severe Alcohol&#8208;Associated Hepatitis, Compared With Pentoxifylline or Placebo&#8208;a Meta&#8208;Analysis of Individual Data From Controlled Trials</article-title>,&#8221; <source>Gastroenterology</source><volume>155</volume>, no. <issue>2</issue> (<year>2018</year>): <fpage>458</fpage>&#8211;<lpage>468</lpage>, <pub-id pub-id-type="doi">10.1053/j.gastro.2018.05.011</pub-id>.<pub-id pub-id-type="pmid">29738698</pub-id></mixed-citation></ref><ref id="liv16137-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="liv16137-cit-0006"><string-name name-style="western"><given-names>M. R.</given-names><surname>Thursz</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Richardson</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Allison</surname></string-name>, et&#160;al., &#8220;<article-title>Prednisolone or Pentoxifylline for Alcohol&#8208;Associated Hepatitis</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>372</volume>, no. <issue>17</issue> (<year>2015</year>): <fpage>1619</fpage>&#8211;<lpage>1628</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa1412278</pub-id>.<pub-id pub-id-type="pmid">25901427</pub-id></mixed-citation></ref><ref id="liv16137-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="liv16137-cit-0007"><string-name name-style="western"><given-names>A.</given-names><surname>Louvet</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Naveau</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Abdelnour</surname></string-name>, et&#160;al., &#8220;<article-title>The Lille Model: A New Tool for Therapeutic Strategy in Patients With Severe Alcohol&#8208;Associated Hepatitis Treated With Steroids</article-title>,&#8221; <source>Hepatology</source><volume>45</volume>, no. <issue>6</issue> (<year>2007</year>): <fpage>1348</fpage>&#8211;<lpage>1354</lpage>, <pub-id pub-id-type="doi">10.1002/hep.21607</pub-id>.<pub-id pub-id-type="pmid">17518367</pub-id></mixed-citation></ref><ref id="liv16137-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="liv16137-cit-0008"><string-name name-style="western"><given-names>S.</given-names><surname>Gaia</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Smedile</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Omed&#232;</surname></string-name>, et&#160;al., &#8220;<article-title>Feasibility and Safety of G&#8208;CSF Administration to Induce Bone Marrow&#8208;Derived Cells Mobilization in Patients With End Stage Liver Disease</article-title>,&#8221; <source>Journal of Hepatology</source><volume>45</volume>, no. <issue>1</issue> (<year>2006</year>): <fpage>13</fpage>&#8211;<lpage>19</lpage>, <pub-id pub-id-type="doi">10.1016/j.jhep.2006.02.018</pub-id>.<pub-id pub-id-type="pmid">16635534</pub-id></mixed-citation></ref><ref id="liv16137-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="liv16137-cit-0009"><string-name name-style="western"><given-names>E.</given-names><surname>Yannaki</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Athanasiou</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Xagorari</surname></string-name>, et&#160;al., &#8220;<article-title>G&#8208;CSF&#8208;Primed Hematopoietic Stem Cells or G&#8208;CSF Per Se Accelerate Recovery and Improve Survival After Liver Injury, Predominantly by Promoting Endogenous Repair Programs</article-title>,&#8221; <source>Experimental Hematology</source><volume>33</volume>, no. <issue>1</issue> (<year>2005</year>): <fpage>108</fpage>&#8211;<lpage>119</lpage>, <pub-id pub-id-type="doi">10.1016/j.exphem.2004.09.005</pub-id>.<pub-id pub-id-type="pmid">15661404</pub-id></mixed-citation></ref><ref id="liv16137-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="liv16137-cit-0010"><string-name name-style="western"><given-names>L.</given-names><surname>Spahr</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Lambert</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Rubbia&#8208;Brandt</surname></string-name>, et&#160;al., &#8220;<article-title>Granulocyte&#8208;Colony Stimulating Factor Induces Proliferation of Hepatic Progenitors in Alcoholic Steatohepatitis: A Randomized Trial</article-title>,&#8221; <source>Hepatology</source><volume>48</volume>, no. <issue>1</issue> (<year>2008</year>): <fpage>221</fpage>&#8211;<lpage>229</lpage>, <pub-id pub-id-type="doi">10.1002/hep.22317</pub-id>.<pub-id pub-id-type="pmid">18537187</pub-id></mixed-citation></ref><ref id="liv16137-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="liv16137-cit-0011"><string-name name-style="western"><given-names>S. M.</given-names><surname>Shasthry</surname></string-name>, <string-name name-style="western"><given-names>M. K.</given-names><surname>Sharma</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Shasthry</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Pande</surname></string-name>, and <string-name name-style="western"><given-names>S. K.</given-names><surname>Sarin</surname></string-name>, &#8220;<article-title>Efficacy of Granulocyte Colony&#8208;Stimulating Factor in the Management of Steroid&#8208;Nonresponsive Severe Alcohol&#8208;Associated Hepatitis: A Double&#8208;Blind Randomized Controlled Trial</article-title>,&#8221; <source>Hepatology</source><volume>70</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>802</fpage>&#8211;<lpage>811</lpage>, <pub-id pub-id-type="doi">10.1002/hep.30516</pub-id>.<pub-id pub-id-type="pmid">30664267</pub-id></mixed-citation></ref><ref id="liv16137-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="liv16137-cit-0012"><string-name name-style="western"><given-names>V.</given-names><surname>Singh</surname></string-name>, <string-name name-style="western"><given-names>A. K.</given-names><surname>Sharma</surname></string-name>, <string-name name-style="western"><given-names>R. L.</given-names><surname>Narasimhan</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bhalla</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Sharma</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Sharma</surname></string-name>, &#8220;<article-title>Granulocyte Colony&#8208;Stimulating Factor in Severe Alcohol&#8208;Associated Hepatitis: A Randomized Pilot Study</article-title>,&#8221; <source>American Journal of Gastroenterology</source><volume>109</volume>, no. <issue>9</issue> (<year>2014</year>): <fpage>1417</fpage>&#8211;<lpage>1423</lpage>, <pub-id pub-id-type="doi">10.1038/ajg.2014.154</pub-id>.<pub-id pub-id-type="pmid">24935272</pub-id></mixed-citation></ref><ref id="liv16137-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="liv16137-cit-0013"><string-name name-style="western"><given-names>C.</given-names><surname>Engelmann</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Herber</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Franke</surname></string-name>, et&#160;al., &#8220;<article-title>Granulocyte&#8208;Colony Stimulating Factor (G&#8208;CSF) to Treat Acute&#8208;On&#8208;Chronic Liver Failure: A Multicenter Randomized Trial (GRAFT Study)</article-title>,&#8221; <source>Journal of Hepatology</source><volume>75</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>1346</fpage>&#8211;<lpage>1354</lpage>, <pub-id pub-id-type="doi">10.1016/j.jhep.2021.07.033</pub-id>.<pub-id pub-id-type="pmid">34364917</pub-id></mixed-citation></ref><ref id="liv16137-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="liv16137-cit-0014"><string-name name-style="western"><given-names>P. D.</given-names><surname>Bradley Malin</surname></string-name>, <article-title>&#8220;Summary of the Assessment of Trinetx Data Privacy Principles Through an Empirical Analysis,&#8221;</article-title><year>2020</year>.</mixed-citation></ref><ref id="liv16137-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="liv16137-cit-0015"><string-name name-style="western"><given-names>E. A. S. L.</given-names><surname>Anon</surname></string-name>, &#8220;<article-title>Clinical Practice Guidelines: Management of Alcohol&#8208;Related Liver Disease</article-title>,&#8221; <source>Journal of Hepatology</source><volume>69</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>154</fpage>&#8211;<lpage>181</lpage>, <pub-id pub-id-type="doi">10.1016/j.jhep.2018.03.018</pub-id>.<pub-id pub-id-type="pmid">29628280</pub-id></mixed-citation></ref><ref id="liv16137-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="liv16137-cit-0016"><string-name name-style="western"><given-names>V.</given-names><surname>Singh</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Keisham</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bhalla</surname></string-name>, et&#160;al., &#8220;<article-title>Efficacy of Granulocyte Colony&#8208;Stimulating Factor and N&#8208;Acetylcysteine Therapies in Patients With Severe Alcohol&#8208;Associated Hepatitis</article-title>,&#8221; <source>Clinical Gastroenterology and Hepatology</source><volume>16</volume>, no. <issue>10</issue> (<year>2018</year>): <fpage>1650</fpage>&#8211;<lpage>1656</lpage>, <pub-id pub-id-type="doi">10.1016/j.cgh.2018.01.040</pub-id>.<pub-id pub-id-type="pmid">29391265</pub-id></mixed-citation></ref><ref id="liv16137-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="liv16137-cit-0017"><string-name name-style="western"><given-names>A.</given-names><surname>Marot</surname></string-name>, <string-name name-style="western"><given-names>A. K.</given-names><surname>Singal</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Moreno</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Deltenre</surname></string-name>, &#8220;<article-title>Granulocyte Colony&#8208;Stimulating Factor for Alcohol&#8208;Associated Hepatitis: A Systematic Review and Meta&#8208;Analysis of Randomised Controlled Trials</article-title>,&#8221; <source>JHEP Reports</source><volume>2</volume>, no. <issue>5</issue> (<year>2020</year>): <elocation-id>100139</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.jhepr.2020.100139</pub-id>.<pub-id pub-id-type="pmid">32775975</pub-id><pub-id pub-id-type="pmcid">PMC7396826</pub-id></mixed-citation></ref><ref id="liv16137-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="liv16137-cit-0018"><string-name name-style="western"><given-names>J. A.</given-names><surname>Tayek</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Stolz</surname></string-name>, <string-name name-style="western"><given-names>D. V.</given-names><surname>Nguyen</surname></string-name>, et&#160;al., &#8220;<article-title>A Phase II, Multicenter, Open&#8208;Label, Randomized Trial of Pegfilgrastim for Patients With Alcohol&#8208;Associated Hepatitis</article-title>,&#8221; <source>EClinicalMedicine</source><volume>54</volume> (<year>2022</year>): <elocation-id>101689</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101689</pub-id>.<pub-id pub-id-type="pmid">36267499</pub-id><pub-id pub-id-type="pmcid">PMC9576807</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>